CoChat

Effects of methimazole on the elimination of irinotecan

Open access

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

PURPOSE: To study the possible pharmacokinetic and pharmacodynamic interactions between irinotecan and methimazole. METHODS: A patient treated for colorectal cancer with single agent irinotecan received methimazole co-medication for Graves' disease. Irinotecan pharmacokinetics and side effects were followed during a total of four courses (two courses with and two courses without methimazole). RESULTS: Plasma concentrations of the active irinotecan metabolite SN-38 and its inactive metabolite SN-38-Glucuronide were both higher (a mean increase of 14 and 67%, respectively) with methimazole co-medication, compared to irinotecan monotherapy. As a result, the mean SN-38 glucuronidation rate increased with 47% during concurrent treatment. Other possible confounding factors did not change over time. Specific adverse events due to methimazole co-treatment were not seen. CONCLUSIONS: Additional in vitro experiments suggest that these results can be explained by induction of UGT1A1 by methimazole, leading to higher SN-38G concentrations. The prescribed combination of these drugs may lead to highly toxic intestinal SN-38 levels. We therefore advise physicians to be very careful in combining methimazole with regular irinotecan doses, especially in patients who are prone to irinotecan toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00280-010-1414-x

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pharmacokinetics of irinotecan and metabolites. a Irinotecan is converted into its 1,000 times more active metabolite SN-38 by carboxylesterases (CES), which are predominately found in the liver. The affinity for this reaction is low, since only a fraction of irinotecan is directly converted into SN-38. Competing with the formation of SN-38 is the CYP3A-mediated inactivation of irinotecan into the metabolites APC and NPC. In turn, carboxylesterases also have the ability to convert both of these compounds into SN-38. SN-38 is glucuronidated by UGT1A into its inactive metabolite SN-38G. In the intestines, β-glucuronidase-producing bacteria can reverse this latter reaction, and thus reactivate SN-38, which causes the dose-limiting toxicity diarrhea. Area under the plasma concentration versus time curves for irinotecan (b), NPC (c), APC (d), SN-38 (e), and SN-38G (f) during all four chemotherapy courses. The open and closed symbols describe the two courses with methimazole and the two courses without methimazole co-treatment, respectively
Fig. 1 Pharmacokinetics of irinotecan and metabolites. a Irinotecan is converted into its 1,000 times more active metabolite SN-38 by carboxylesterases (CES), which are predominately found in the liver. The affinity for this reaction is low, since only a fraction of irinotecan is directly converted into SN-38. Competing with the formation of SN-38 is the CYP3A-mediated inactivation of irinotecan into the metabolites APC and NPC. In turn, carboxylesterases also have the ability to convert both of these compounds into SN-38. SN-38 is glucuronidated by UGT1A into its inactive metabolite SN-38G. In the intestines, β-glucuronidase-producing bacteria can reverse this latter reaction, and thus reactivate SN-38, which causes the dose-limiting toxicity diarrhea. Area under the plasma concentration versus time curves for irinotecan (b), NPC (c), APC (d), SN-38 (e), and SN-38G (f) during all four chemotherapy courses. The open and closed symbols describe the two courses with methimazole and the two courses without methimazole co-treatment, respectivelyCC BY-NC · PubMed Central
Fig. 2 In vitro experiments. a Effects of methimazole (striped bars) and fluconazole (open bars) on the formation of NPC, APC, and SN-38 during co-incubation with irinotecan, and effects of methimazole (striped bars) and ketoconazole (open bars) on the formation of SN38G during co-incubation with SN-38. The black bars represent the formation of irinotecan metabolites in the absence of any (potential) inhibitor. b Methimazole induces UGT1A1 mRNA levels. HCT116 cells were cultured in the presence or absence (control) of various concentrations of methimazole. At 5 (cross-hatched bar), 24 (hatched bar) and 48 (white bar) hours total RNA was isolated and used to measure UGT1A1 mRNA levels by quantitative RT-PCR (Taqman™). Depicted is the expression of UGT1A1 compared to the control UGT1A1 levels (black bar), which are arbitrarily set at 1. Error bars indicate 2 × standard deviation (n = 3)
Fig. 2 In vitro experiments. a Effects of methimazole (striped bars) and fluconazole (open bars) on the formation of NPC, APC, and SN-38 during co-incubation with irinotecan, and effects of methimazole (striped bars) and ketoconazole (open bars) on the formation of SN38G during co-incubation with SN-38. The black bars represent the formation of irinotecan metabolites in the absence of any (potential) inhibitor. b Methimazole induces UGT1A1 mRNA levels. HCT116 cells were cultured in the presence or absence (control) of various concentrations of methimazole. At 5 (cross-hatched bar), 24 (hatched bar) and 48 (white bar) hours total RNA was isolated and used to measure UGT1A1 mRNA levels by quantitative RT-PCR (Taqman™). Depicted is the expression of UGT1A1 compared to the control UGT1A1 levels (black bar), which are arbitrarily set at 1. Error bars indicate 2 × standard deviation (n = 3)CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 9

Metadata

Authors
van der Bol, J. M., Visser, T. J., Loos, W. J., de Jong, F. A., Wiemer, E. A. C., van Aken, M. O., Planting, A. S., Schellens, J. H., Verweij, J., & Mathijssen, R. H. J.
Affiliations
  • Erasmus MC (NL)
  • Utrecht University (NL)
Corresponding author
Mathijssen, Ron H. J.
Venue
Cancer Chemotherapy and Pharmacology
Published
2010-08-01
Volume
67
Issue
1
Pages
231-236
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W2114917381
Cited by
9
References
21
Citations by year
2023: 1 · 2022: 1 · 2021: 1 · 2018: 1 · 2015: 1 · 2014: 2 · 2012: 1
FWCI
0.65
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Cancer Chemotherapy and Pharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
irinotecan, methimazole, drug-drug interactions, SN-38, SN-38 glucuronide, SN-38 glucuronidation, pharmacokinetic interactions, pharmacodynamic interactions, colorectal cancer, Graves' disease, irinotecan toxicity, intestinal toxicity
MeSH terms
Irinotecan, UGT1A1 Enzyme, Antineoplastic Agents, Phytogenic, Camptothecin, Drug Interactions, Graves Disease, Humans, Male, Methimazole, Middle Aged, Antithyroid Agents, Glucuronosyltransferase, Colorectal Neoplasms, Glucuronides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.